Prognostic value of the systemic inflammation response index in human malignancy

Systemic inflammation is closely related to the occurrence and development of tumours. Based on preoperative neutrophil, monocyte, and lymphocyte counts, a new systemic inflammation response index (SIRI) was established, and the predictive ability of the SIRI for the survival of patients with adenocarcinoma of the oesophagogastric junction (AEG) was evaluated by propensity score matching (PSM) analysis. A total of 302 AEG patients undergoing radical surgery were studied. Univariate and multivariate analyses were performed using Cox proportional hazards regression models. Time-dependent receiver operating characteristic (ROC) curves were used to compare the predictive capabilities of the SIRI. PSM was implemented to balance the baseline characteristics. The results showed that the SIRI, PLR, NLR, and MLR were associated with overall survival (OS) in AEG patients based on the Kaplan-Meier survival analysis. Multivariate analysis demonstrated that the SIRI was an independent prognostic factor. The AUC for the SIRI was significantly greater than that for the NLR, PLR, and MLR in predicting the 3- and 5-year OS of AEG patients. In PSM analysis, the SIRI remained an independent prognostic indicator of OS in AEG patients. The SIRI is a novel, simple, and inexpensive prognostic predictor for AEG. The prognostic value of the SIRI is superior to that of the PLR, NLR, and MLR. The SIRI can be used to distinguish the prognosis of AEG patients with different TNM stages and can be an important supplement to TNM staging.

Download Full-text

Prognostic value of the systemic inflammation response index in patients with aneurismal subarachnoid hemorrhage and a Nomogram model construction

British Journal of Neurosurgery ◽

10.1080/02688697.2020.1831438 ◽

2020 ◽

pp. 1-7

Author(s):

Peng Zhang ◽

Yuping Li ◽

Hengzhu Zhang ◽

Xiaodong Wang ◽

Lun Dong ◽

...

Keyword(s):

Subarachnoid Hemorrhage ◽

Systemic Inflammation ◽

Prognostic Value ◽

Model Construction ◽

Inflammation Response ◽

Response Index

Download Full-text

The Prognostic Value of Systemic Inflammation Response Index in Cholangiocarcinoma Patients

Cancer Management and Research ◽

10.2147/cmar.s317954 ◽

2021 ◽

Vol Volume 13 ◽

pp. 6263-6277

Author(s):

Bao Jin ◽

Wenmo Hu ◽

Si Su ◽

Haifeng Xu ◽

Xin Lu ◽

...

Keyword(s):

Systemic Inflammation ◽

Prognostic Value ◽

Inflammation Response ◽

Response Index

Download Full-text

Systemic Inflammation Response Index as a Prognostic Marker in Cancer Patients: A Systematic Review and Meta-Analysis of 38 Cohorts

Dose-Response ◽

10.1177/15593258211064744 ◽

2021 ◽

Vol 19 (4) ◽

pp. 155932582110647

Author(s):

Qian Zhou ◽

Si Su ◽

Wen You ◽

Tao Wang ◽

Tong Ren ◽

...

Keyword(s):

Systemic Inflammation ◽

Prognostic Value ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Progression Free Survival ◽

Prognostic Indicator ◽

Free Survival ◽

Inflammation Response ◽

Response Index

Background The systemic inflammation response index (SIRI), a novel and cost-effective serum biomarker, is associated with prognosis in patients with cancer. However, the prognostic value of the SIRI in cancer remains unclear. This study aimed to evaluate the potential role of the SIRI as a prognostic indicator in cancer. Methods Reports in which the prognostic value of the SIRI in cancer was evaluated were retrieved from electronic databases. The pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated to evaluate the prognostic significance of the SIRI. The odds ratio (OR) was also calculated to explore the association between the SIRI and clinicopathological features. Results This study included 30 retrospective studies with 38 cohorts and 10 754 cases. The meta-analysis indicated that a high SIRI was associated with short overall survival (OS) (HR = 2.04, 95% CI = 1.82–2.29, P < .001) and disease-free survival (DFS)/recurrence-free survival (RFS)/progression-free survival (PFS) (HR = 2.08, 95% CI = 1.84–2.34, P < .001). Subgroup analysis showed that the prognostic value of the SIRI was significant in all kinds of cancer included. Moreover, the SIRI was significantly correlated with sex, tumor size, T stage, N stage, TNM stage, and lymphovascular invasion. Conclusion The pretreatment SIRI could be a promising universal prognostic indicator in cancer.

Download Full-text

Prognostic and clinical significance for the combination of systemic inflammation response index and platelet--lymphocyte ratio in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer

10.22541/au.159411425.59706215 ◽

2020 ◽

Author(s):

Xin Yin ◽

Tianyi Fang ◽

Xuan Lin ◽

Xiliang Cong ◽

Yimin Wang ◽

...

Keyword(s):

Gastric Cancer ◽

Clinical Significance ◽

Systemic Inflammation ◽

Esophagogastric Junction ◽

Inflammation Response ◽

Lymphocyte Ratio ◽

Response Index ◽

Platelet Lymphocyte Ratio

Download Full-text

The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

Journal of Oncology ◽

10.1155/2020/8832145 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8

Author(s):

Ahmet Kucuk ◽

Emine Elif Ozkan ◽

Sukran Eskici Oztep ◽

Huseyin Mertsoylu ◽

Berrin Pehlivan ◽

...

Keyword(s):

Systemic Inflammation ◽

Concurrent Chemoradiotherapy ◽

Cohort Analysis ◽

Prognostic Significance ◽

Small Cell ◽

Survival Outcomes ◽

Small Cell Lung ◽

Inflammation Response ◽

Response Index ◽

Limited Stage

Background. Recent studies have indicated that the systemic inflammation response index (SIRI) can efficiently predict survival outcomes in various tumor types. Thusly, in absence of comparable investigations in limited-stage small-cell lung cancers (LS-SCLCs), we aimed to retrospectively evaluate the prognostic utility of SIRI in LS-SCLC patients treated with concurrent chemoradiotherapy (CRT). Patients and Methods. Present multi-institutional retrospective analysis incorporated LS-SCLC patients treated with CRT at three academic radiation oncology centers between January 2007 and December 2018. The SIRI was calculated by using the peripheral blood neutrophil (N), monocyte (M), and lymphocyte (L) counts acquired in the last ≤7 days before the commencement of the CRT: SIRI = N × M/L. Accessibility of pretreatment SIRI cutoff that may stratify the study population into two gatherings with distinctive overall survival (OS) results was evaluated by utilizing the receiver operating characteristic (ROC) curve analysis. Primary objective was the association between the SIRI values and the OS results. Results. Search for the availability of an ideal SIRI cutoff that may stratify the entire patients’ population into two particular groups with distinctive OS outcomes identified the 1.93 value (area under the curve (AUC): 72.9%; sensitivity: 74.6%; specificity: 70.1%): Group 1: SIRI <1.93 (N = 71) and Group 2: SIRI ≥1.93 (N = 110), respectively. At a median follow-up of 17.9 (95% CI: 13.2–22.6) months, 47 (26.0%) patients were still alive (47.9% for SIRI <1.93 versus 18.3% for SIRI ≥1.93; p < 0.001 ). Kaplan–Meier comparisons between the two SIRI groups showed that the SIRI <1.93 cohort had significantly longer median OS (40.5 versus 14.2 months; p < 0.001 ) than the SIRI ≥1.93 cohort. Similarly, the 3- (54% versus 12.6%) and 5-year (33% versus 9.9%) OS rates were also numerically superior in the SIRI <1.93 cohort. Results of the multivariate analyses uncovered that the prognostic significance of the SIRI on OS outcomes was independent of the other confounding variables. Conclusions. The results of this retrospective multi-institutional cohort analysis suggested that a pre-CRT SIRI was a strong and independent prognostic biomarker that reliably stratified LS-SCLC patients into two cohorts with significantly different OS outcomes.

Download Full-text